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summary
Pain is the hallmark symptom of fibromyalgia (FM) and other related syndromes, but quite different from that 
of other rheumatic diseases, which depends on the degree of damage or inflammation in peripheral tissues. 
Sufferers are often defined as patients with chronic pain without an underlying mechanistic cause, and these 
syndromes and their symptoms are most appropriately described as “central pain”, “neuropathic pain”, “non-
nociceptive pain” or “central sensitivity syndromes”. The pain is particular, regional or widespread, and mainly 
relates to the musculoskeletal system; hyperalgesia or allodynia are typical. Its origin is currently considered to 
be distorted pain or sensory processing, rather than a local or regional abnormality. 
FM is probably the most important and extensively described central pain syndrome, but the characteristics 
and features of FM-related pain are similar in other disorders of particular interest for rheumatologists, such as 
myofascial pain syndromes and temporo-mandibular joint disorders, and there is also an intriguing overlap be-
tween FM and benign joint hypermobility syndrome. This suggests that the distinctive aspects of pain in these 
idiopathic or functional conditions is caused by central nervous system hypersensitivity and abnormalities.
Pharmacological and non-pharmacological therapies have been suggested for the treatment of these conditions, 
but a multidisciplinary approach is required in order to reduce the abnormal cycle of pain amplification and the 
related maladaptive and self-limiting behaviours.
Key words: Fibromyalgia, Pain, Central pain syndromes, Myofascial pain syndromes, Temporo-mandibular disorders, Be-
nign joint hypermobility syndrome.
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n	 INTRODUCTION
Pain is the hallmark symptom of fi-bromyalgia (FM) and other related 
syndromes. The pain of FM is quite dif-
ferent from that of other rheumatic dis-
eases and, unlike arthritis, osteoarthritis 
or other painful soft tissue conditions, 
cannot be adequately explained on the 
basis of the degree of peripheral tissue 
inflammation or damage. Sufferers are of-
ten defined as patients with chronic pain 
without an underlying mechanistic cause, 
and those syndromes and symptoms form 
part of a much larger continuum whose 
many names include functional somatic 
syndromes, medically unexplained symp-
toms, chronic multi-symptom illness, and 
somatoform disorders (1), as well as more 
appropriate contemporary terms such as 
“central pain”, “neuropathic pain”, and 
“non-nociceptive pain” (2). However, 
probably the best nosological term for 
these complaints is that of “central sen-
sitivity syndromes” (CSS) proposed by 
Yunus (3, 4).
Other rheumatic diseases do not have pain 
as their dominant symptom, most impor-
tant feature or main patient complaint, and 
their diagnostic and classification criteria 
do not often include pain as a specific 
domain, but the conditions mentioned 
above would not exist without the par-
ticular and usually unremitting regional 
or widespread pain that mainly affects 
the musculoskeletal system. Patients typi-
cally suffer from hyperalgesia (increased 
pain induced by normally painful stimuli) 
No
n-c
om
me
rci
al 
us
 on
ly
Reumatismo 1/2014 73
reviewPain in fibromyalgia and related conditions
or allodynia (pain induced by normally 
non-painful stimuli), thus suggesting that 
the original problem is distorted pain or 
sensory processing rather than a local or 
regional abnormality.
FM is probably the most important and 
widely described of the central pain syn-
dromes, but other idiopathic or functional 
disorders also suggest that the pain does 
not come from the periphery but is due to 
an underlying aberrant mechanism of the 
central nervous system (CNS) that causes 
hypersensitivity and accounts for the dis-
tinctive aspects of the related pain.
The concept of central sensitisation or 
sensitivity
Central sensitisation (CS) can be defined 
as an incorrect and abnormal response of 
the CNS to a peripheral stimulus, due to 
neuronal hyperexcitability and hypersen-
sitivity, and characterised by prolonged or 
persistent pain. CS has many neurophysi-
ological aspects, including enhanced spi-
nal cord dorsal horn neuronal excitability 
and increased spontaneous neuronal activ-
ity, an enlarged receptive field (the “wind-
up” phenomenon), and increased stimuli 
transmitted by large- and small-diameter 
primary afferent fibers (5). These inap-
propriately anomalous events lead to an 
exaggerated painful perception of normal 
non-painful stimuli, such as touch or gen-
tle pressure (i.e. allodynia).
Persisting stimuli from the periphery (due 
to the activation of a variety of nociceptors 
in the presence of inflammatory mediators 
such as bradykinin, serotonin, histamine, 
prostaglandins, and substance P), periph-
eral sensitisation, converging phenomena 
at wide dynamic range neuron level in the 
dorsal horn, and the wind-up phenomenon 
cause what is known as “neuroplasticity”.
The wind-up phenomenon, which progres-
sively increases the response of secondary 
neurons (following repeated stimulation 
of C fibres), is mediated by N-methyl-D-
aspartate (NMDA), and NMDA receptors 
seem to be strictly related to the escalating 
hyperexcitability of second-order neurons.
It is not clear whether these phenomena 
are due to spinal sensitisation maintained 
by the input of tonic impulses from somat-
ic tissues, a facilitating mechanism within 
the brain, or an abnormal mechanism of 
descending facilitation (6). Neurotrans-
mitter abnormalities also play a role in 
pain and sensory processing by increas-
ing “volume control” (1, 7), but long-term 
neuroplasticity itself can lead to self-sus-
taining CS without the need for further 
stimuli (8). 
FM and other functional somatic syn-
dromes characterised by disturbed central 
pain processing are not characterised by 
a demonstrable inflammation or mechani-
cal tissue damage, injury, or entrapped pe-
ripheral nerves, but there is no doubt that 
they have some neuropathic aspects and 
that any combination of peripheral, neuro-
pathic and central pain may be present in 
a given individual (1).
Finally, neurotransmitters, cytokines or 
chemokines can also activate glial cells, 
and thus contribute to secondary enhance-
ment of the CNS and CS (5, 9).
CS therefore seems to be the pivotal com-
ponent of the central pain mechanism and 
process of amplification that lead to the 
clinical manifestation of sensitivity (4).
n	 FIBROMYALGIA
Pain definitions and classification and 
diagnostic criteria
The most common and distinctive symp-
tom of FM, one of large group of soft tis-
sue pain syndromes, is pain and FM is cur-
rently classified as a chronic widespread 
pain (CWP) characterised by extensive 
hyperalgesia and allodynia (10).
The 1990 American College of Rheuma-
tology (ACR) definition for clinical trials 
stated that FM is a CWP condition with 
characteristic tender points upon physi-
cal examination, often associated with 
a constellation of symptoms such as fa-
tigue, sleep disturbances, headache, irrita-
ble bowel syndrome, and mood disorders 
(11). Widespread pain for at least three 
months and tenderness at definite points 
were the two compulsory major criteria 
for classifying adult FM. This definition 
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is still broadly accepted, although further 
elucidations and revisions have been pro-
posed.
Pain is usually associated with fatigue and 
sleep disturbances in virtually all patients 
with FM, and these are considered the 
three key features of the syndrome (12).
The 1992 Copenhagen declaration em-
phasised that FM is the commonest cause 
of chronic widespread musculoskeletal 
pain in a non-articular condition, predom-
inantly involving muscles (13).
CWP for at least three months is the req-
uisite unifying every attempt to draw up 
classification or diagnostic criteria during 
the time (11, 14, 15). 
The new ACR preliminary diagnostic cri-
teria for FM suggest the use of the Wide-
spread Pain Index as a method of identi-
fying and enumerating the painful areas 
reported by patients, although many other 
somatic symptoms are considered crucial 
with the view that FM is a CSS. They also 
introduced an innovative and debatable 
concept of widespread pain that encom-
passes the possibility that it can be con-
sidered diffuse even if it is regional. 
Characteristics of pain
Pain is usually present in all four limbs, 
as well as the upper or lower back; many 
patients state that they “hurt all over”, 
and this symptom is often a discriminant 
when evaluating patient complaints. It 
may be regional or generalised and “non-
anatomically” distributed, and perceived 
as originating in muscles or deep in bones 
(16), and rarely articular (17); no structural 
or nerve root distribution can be detected. 
Hyperalgesia and allodynia, persistent 
pain, summation effects, skin hyperpathia, 
and tenderness upon examination are the 
most common characteristics, and patients 
describe their pain as sharp, burning, sear-
ing, tingling, shooting or stabbing, deeply 
aching, or feeling bruised all over (10, 16). 
Its intensity is aggravated by cold or humid 
weather, anxiety or stress, overuse or inac-
tivity, poor sleep (18, 19) and noise (20). 
The pain often corresponds to widespread, 
regional or localised myalgia, not neces-
sarily confined to the tender points, and 
with widely varying characteristics. Leg 
cramps are reported in approximately 
40% of FM patients as against 2% of con-
trols (21).
In a very recent and extensive study, FM 
pain reached the utmost level of intensity 
among rheumatic diseases, with a mean 
value of 71.7 measured on a Visual Ana-
logue Scale (22).
Finally, tenderness is the unique and typi-
cal sign, but is not limited to the canonic 
tender points (23)
Pain mechanisms
The pathophysiology of FM is still un-
clear, although many of its aspects have 
been clarified over the last few decades. 
The different research areas are now well 
defined: genetics, triggers, psychophysi-
ological abnormalities, autonomic nerv-
ous system dysfunction, neurotransmit-
ter and neuroendocrine dysfunctions, and 
cerebral abnormalities, but CNS hyper-
sensitivity is the most relevant event and 
CS appears to be its main mechanism. 
Emerging evidence suggests that people 
experiencing regional pain may develop 
widespread pain: for example, some au-
thors have found that 10-22% of subjects 
with chronic neck pain or whiplash inju-
ries develop CWP or FM (24, 25).
FM patients also present neurotransmitter 
abnormalities at different levels and vari-
ous neuropeptides can induce the expres-
sion of cytokines at nerve endings, thus 
increasing nociceptive sensitivity (6, 26, 
27). In addition, decreased thresholds of 
heat (28), auditory tones (29) and electrical 
stimulation (30, 31) have been demonstrat-
ed, which suggests that FM (like its related 
syndromes) may involve the biological am-
plification of all sensory stimuli (32).
Can the neurochemical model completely 
and entirely explain CS? Or are psycho-
logical and sociological aspects (partially 
or totally) additional factors promoting the 
change in pain perception? Familial predis-
position, genetic polymorphism, and dif-
ferences between male and female patients 
must be taken into account (33-35).
Neuroimaging of brain activity has al-
lowed us to understand some of the cer-
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ebral mechanisms and abnormalities in-
volved in CS. Some authors have found 
increased activity in the brain’s pain 
processing regions (the rostral anterior 
cingulate cortex and pre-frontalcortical 
areas) during painful mechanical stimu-
lation (36, 37), and the insula seems to 
be the most reliably hyperactive region 
(1). Increased sensitivity in FM has been 
demonstrated by a controlled study of 
the effects of an evoked painful stimulus: 
equivalent pressure stimuli induced sig-
nificantly greater activity in the patients, 
whereas similar levels of perceived pain 
intensity evoked similar neural activity 
in a network of brain regions involved in 
pain processing in patients and controls 
(32, 38). It is not always easy to show 
whether functional magnetic resonance 
(fMR) findings in FM are only due to 
hyperalgesia or reflect cognitive effects. 
Experimental evidence strongly supports 
the view that FM symptoms are related to 
dysfunctions in the CNS associated with 
multiple changes in the brain, but whether 
long-term ongoing pain causes the chang-
es, or the changes cause the pain, is still an 
open question (39).
Neuroendocrine abnormalities play an 
important role in the pathogenesis of FM. 
The hypothalamic-pituitary-adrenal and 
hypothalamic-pituitary-thyroid axes show 
functional alterations, and it is known 
that chronic stress can induce the func-
tional exhaustion of stress responses and 
contribute to increased pain perception. 
FM patients have an abnormal response 
to stress and an inadequate reaction to a 
number of stressful events (7). Chronic 
stress and persistent pain can also modu-
late emotional responses. The amygdala 
seems to play a dual facilitatory and in-
hibitory role in modulating pain behav-
iour and nociceptive processing at differ-
ent levels of the pain neuraxis. Negative 
or positive emotions may respectively 
amplify or reduce the pain perception as a 
result of amygdala plasticity (40).
Other conditions may influence or alter 
the perception of pain. Relationships be-
tween sleep disturbances and pain in FM 
have been noted since the first study dem-
onstrating that sleep deprivation induces 
FM-like tenderness (41), and various re-
searchers have suggested a bidirectional 
relationship between non-restorative sleep 
and pain in FM (42). The association be-
tween FM and depression and anxiety has 
been confirmed (43, 44) and both depres-
sion and anxiety (often manifest in FM 
patients) can affect the ability to cope with 
everyday life events. Moreover, emotional 
and cognitive processes, which depend on 
individual vulnerability and strength, may 
affect responses (6). A close correlation 
between depression/anxiety and FM ac-
tivity has recently been demonstrated us-
ing the FM Assessment Status Index (45).
Lastly, some fMR findings are highly 
important. In the presence of FM-related 
major depressive disorder, significant 
activity has been detected in the brain 
regions traditionally related to the affec-
tive component of pain, which suggests 
that pain can be modulated by depression 
(46). The experience of pain is multidi-
mensional and subjective, and it has been 
demonstrated that patients who believe in 
their personal ability to control their pain 
fare better than those who believe that it 
is due to external factors or influences. 
The former (who belong to the so-called 
“internal locus of control”) show greater 
activation in the areas involving the evalu-
ation of pain than the latter, who belong to 
the “external locus of control” and show 
a greater response in the areas involving 
sensory integration (38, 47).
Finally, catastrophising behaviour has a 
significant influence on pain perception 
and is strictly related to the brain regions 
that mediate attention, anticipation or 
emotional response to pain (37).
n	 RELATED CONDITIONS
Pain is the key symptom in some FM-re-
lated conditions or associated syndromes. 
The construct of CSS elegantly and fairly 
explains the concept of an overlapping 
or similar group of syndromes without a 
structural pathology that are characterised 
by the common mechanism of CS. These 
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share a number of features and biopatho-
physiological mechanisms, and have be-
come better defined over time. In addition 
to FM, the latest redefinition of the CSS 
family includes twelve functional disor-
der (Tab. I). Depression and Gulf war syn-
drome have been postulated as potential 
new members (3, 8).
A number of these conditions present mus-
culoskeletal pain, usually in the form of 
chronic local, regional or widespread pain.
Myofascial pain syndrome (MPS) and 
temporo-mandibular joint disorders (TM-
JDs) are musculoskeletal conditions of 
particular interest for rheumatologists. 
Benign joint hypermobility syndrome 
(JHS), which does not belong to the CSS 
family and is generally considered the 
least severe and most frequent type of 
Ehlers-Danlos syndrome (EDS), has simi-
lar features and an intriguing overlap with 
FM.
Myofascial pain syndromes
Pain definitions and diagnostic criteria
MPS is frequent condition in the general 
population and one of the most common 
causes of pain and dysfunction among 
musculoskeletal symptoms. Myofascial 
trigger point pain syndrome is the name 
that best describes the specific clini-
cal manifestation of muscle pain arising 
from trigger points. Its general population 
prevalence is unknown, but its prevalence 
among patients complaining of pain any-
where in the body ranges from 30% to 
93% (48, 49). The pain typically origi-
nates from a myofascial trigger point (TP) 
that usually causes a localised and referred 
response associated with a complex of 
sensory, motor and autonomic symptoms. 
Mandatory criteria for a diagnosis of MPS 
are a patient report of pain and finding the 
TP in a taut palpable band. The pain is lo-
calised at a specific point along the band 
and in an expected referred area for a giv-
en TP. Exquisite and localised tenderness 
and the reproduction of spontaneously 
perceived pain by TP pressure are two of 
the re-defined 1999 Simons criteria (50) 
(Tab. II). A survey of expert American 
clinicians pointed out that a regional dis-
tribution of the symptoms and signs, the 
presence of TP, and a normal neurological 
examination are the minimal criteria for 
the diagnosis of MPS (51), however, there 
are no universally accepted clinical crite-
ria for a diagnosis of MPS.
Characteristics of pain
MPS patients usually present deep, ten-
sive and constrictive somatic pain that is 
occasionally cramp-like and may have a 
sudden or gradual onset. It varies in inten-
sity, may be continuous or intermittent, 
Table II - Myofascial pain syndrome - Simons’ re-
defined 1999 diagnostic criteria.
major criteria
Localized spontaneous pain
Spontaneous pain or altered sensations in the 
expected referred area for a given TP (target area)
A taut, palpable band in an accessible muscle
exquisite, localized tenderness in a precise point 
along the taut band
A certain degree of reduced range of movement when 
measurable
minor criteria
reproduction of spontaneously perceived pain and 
altered sensations by pressure on the TP
elicitation of an local twitch response of muscle ﬁbers 
by transverse ‘snapping’ palpation or by needle 
insertion into the TP
Pain relieved by muscle stretching or injection of the 
TP
Diagnosis: major criteria + one out of three minor 
criteria. 
TP, trigger points.
Table I - Central sensitivity syndrome.
Fibromyalgia
Chronic fatigue syndrome
irritable bowel syndrome
Tension-type headache
Migraine
Temporo-mandibular disorders
Myofascial pain syndrome
restless legs syndrome
Periodic limb movements in sleep
Multiple chemical syndrome
Primary dysmenorrhea
Female urethral syndrome and interstitial cystitis
Post-traumatic stress syndrome
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and is generally present at rest (less fre-
quently during movement). Clearly dis-
tinguishable, pain is spontaneous, and the 
related TP is defined “active”. Tenderness 
upon localised compression is another im-
portant characteristic that may also appear 
if the TP is silent (i.e. in the absence of 
spontaneous pain); in this case, the TP is 
defined “latent” and should be properly 
identified in order to prevent possible evo-
lution (50). TP palpation or therapeutic in-
jection may elicit a local twitch response 
of muscle fibres (some authors consider 
this fleeting response one of the hallmarks 
of MPS).
MPS pain may be localised to the area of 
the affected muscle or at a distance from 
it, and its pattern is typical for each mus-
cle. Patients do not usually complain of 
articular discomfort, although some re-
ferred areas correspond to a joint. MPS 
frequently affects the muscles working 
against gravity, particularly the neck and 
low back, head, shoulders and hips. Weak-
ness, stiffness, fatigue and poor working 
tolerance are frequent, and autonomic 
dysfunction may be present depending on 
the muscle site (52, 53).
Finally, the differences between MPS 
and FM pain must be considered because 
about 70% of FM patients also have a lo-
cal or regional MPS (54, 55). MPS and 
FM may overlap, but multi-regional MPS 
may be mistakenly diagnosed as FM and 
physicians must therefore recognise the 
characteristics of the pain listening to pa-
tient’s complaints.
Pain mechanism
MPS is strictly regional, and the pain and 
sensory changes are confined to the af-
fected area. The pain threshold is low at 
TP level (56, 57). In painful areas, the 
lowered pain threshold not only involves 
the muscle, but also the overlying subcu-
tis and skin whereas, in non-painful areas, 
the threshold is normal (52).
The crucial element for the development 
of a TP is probably dysfunctional neuro-
muscular endplate activity. Spontaneous 
endplate activity has been demonstrated at 
the so-called “active loci” (i.e. the motor 
endplates). Sensitised nociceptors that ac-
count for local and referred pain are “sen-
sitive loci”. 
Multiple “sensitive” and “active” loci rep-
resent a TP region in which the spontane-
ous release of acetylcholine (Ach) seems 
to be responsible for endplate hyperactiv-
ity (52, 56, 58), and needle and surface 
electromyography seems to corroborate 
this (56, 59). Increased Ach concentra-
tions in the synaptic cleft, changes in the 
activity of a number of Ach receptors, and 
changes in Ach esterase activity may ex-
plain the increased endplate electrical ac-
tivity of the active TP.
Pain occurs because of the local release of 
substances from damaged muscle, or dur-
ing the course of ischemia or exercise; these 
substances activate muscle nociceptors that 
increase motor endplate activity (58). Un-
accustomed eccentric exercise that stresses 
a muscle beyond its tolerance is probably 
the main cause of the TP. The consequent 
hypoperfusion leads to an acidic milieu and 
hypoxia that provoke increased Ach activ-
ity and miniature endplate potentials, and 
a substantial increase in the release of cal-
citonin gene-related peptide. The terminal 
consequences of the cascade are sarcomere 
hypercontraction due to the continuous re-
lease and inadequate re-uptake of calcium 
ions, and taut band formation. If these per-
sist, hypoxia and nociceptive substances 
cause a negative, self-maintaining cycle 
leading to chronic hypersensitivity to pain 
(56, 58, 60).
It is widely accepted that MPS becomes a 
chronic form of pain and other complaints 
unless promptly well treated. In the case 
of chronicity, the continuous barrage of 
nociceptive input from an active TP may 
induce CS and the consequent spreading 
of the pain to other regions. Active TPs 
may be inactivated by therapy, but usually 
recur in the presence of triggering condi-
tions, and this may play a role in the onset 
of FM in subjects with predisposing fac-
tors. Furthermore, tenderness and referred 
pain related to chronic musculoskeletal 
pain may be due to peripheral and central 
sensitisation, both of which are probably 
essential events in the transition from 
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acute to chronic pain. Moreover, persis-
tent painful inputs from a TP may increase 
the degree of CS at different levels of the 
CNS; consequently, the transmission of 
pain messages due to other conditions is 
facilitated (52, 61).
Finally, the mechanisms underlying two 
characteristics of TPs are not clearly 
understood: secondary TP (a nocicep-
tive focus in a different muscle when the 
primary TP is active) and referred pain 
from the primary TP probably represent a 
combination of local sensitivity and CS. 
A secondary TP could be due to the neu-
rogenic expression of CS; neurogenically 
mediated inflammation causes the release 
of inflammatory mediators and neuro-
peptides, thus leading to sensitisation of 
peripheral nociceptors and, subsequently, 
TP formation (62, 63). Referred pain from 
Figure 1 - Clues to diagnosis of functional somatic syndromes presenting with temporoman-
dubular disorders (modified from Suma S, veerendra Kumar B. Temporomandibular disorders 
and functional somatic syndromes: deliberations for the dentist. indian J Dent res. 2012; 23: 
529-36).
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a TP may be attributable to central hyper-
excitability phenomena such as conver-
gence and facilitation, in the same way as 
referred pain arises from the viscera (64), 
because of the spread of CS to adjacent 
spinal segments (65). 
Temporo-mandibular joint disorders
TMJDs are a comprehensive term that 
embraces a number of clinical problems 
involving the masticatory muscles, the 
temporo-mandibular joint and associated 
structures; it belongs to the CSSs and 
shares many of non-painful symptoms.
The most important feature is pain, fol-
lowed by restricted mandibular move-
ment and noises from the joints during 
jaw movement. It has a negative impact 
on the quality of life and increases stress 
levels (66, 67) in a manner that is strictly 
related to difficulties in management and, 
therefore, chronicity. TMJDs are very 
common: it affects about 20-30% of the 
adult population to some degree (68), and 
60-70% of the general population have at 
least one sign of the disorder (69). It usu-
ally appears in people aged 20-40 years, 
and is more common in females; TMJDs 
are the second most frequent cause of oro-
facial paon after that of dental origin (70).
Trauma, inflammation, aging, parafunc-
tional habits, infections, and neoplasms 
must all be considered in the differential 
diagnosis before considering TMJD a 
CSS or functional somatic syndrome (as 
other authors prefer) (71) (Fig. 1).
Pain definitions and classification criteria
TMJDs are a cluster of related disorders 
with many common features that has 
widely varying definitions and terminol-
ogy, although the term “temporo-mandib-
ular joint disorder” is generally favoured. 
There are no universally accepted classifi-
cation or diagnostic criteria.
The Research Diagnostic Criteria (72, 73) 
consider temporo-mandibular disorders 
(TMD) in 2 axes; axis I refers to physical 
aspects, and axis II involves the assessment 
of psychological status, mandibular func-
tion and TMD-related psychosocial dis-
ability (74). Axis I is further divided into 
three general groups: group I are muscle 
disorders; group II are disc displacements; 
and group III are joint disorders (72). Pain 
is the main symptom of all these groups, 
although limited range and noises from 
the joint during mandibular movement are 
cardinal symptoms and signs in TMJDs. It 
may be acute or chronic (when the symp-
toms last for more than three months), and 
may be often and indiscriminately referred 
to muscle or joint structures. TMJD-related 
pain has been variously classified as “fa-
cial arthromyalgia”, “myofacial pain dys-
function syndrome”, “craniomandibular 
dysfunction”, “myofacial pain dysfunc-
tion”, “masticatory myalgia”, “mandibular 
dysfunction”, or headache or facial pain by 
different scientific societies, academies or 
organisations.
Characteristics of pain
The cardinal features are included in the 
definitions of the disorder. Tenderness 
upon palpation of the masticatory muscles 
or of the joint itself (usually just in front of 
the ear) is another characteristic of TMJDs 
pain. Manipulation or function (chewing, 
clenching or yawning) usually increases 
the level of pain (75), which is often worse 
upon waking than during the night or rest 
(76). The pain is usually described as dull 
or aching, poorly localised, intermittent 
or (sometimes) constant, but rarely severe 
(77, 78). It is more usually unilateral than 
bilateral (79), and may occur not only in 
the joint region, but can also be referred to 
the temple, neck and shoulders.
Pain mechanism
Like other CSS, TMJD has a multifactori-
al etiology, and the presence of predispos-
ing, initiating, precipitating and perpetuat-
ing factors need to be recognised (except 
when it is due to structural causes) (80) 
for the construct of the bio-psychosocial 
model that bonds all of the members of 
the CSS family. As in FM, MPS and other 
related syndromes, CS is the most plau-
sible underlying mechanism that progres-
sively makes the pain chronic and locally 
widespread.
The pain discourages the use of the mas-
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ticatory system as a “fear avoidance” be-
haviour, which leads to reduced muscle 
elasticity, tone, strength, endurance and, 
eventually, incomplete mouth opening 
(81). Anxiety, depression, somatisation, 
and sleep deprivation are important risk 
factors for the development of TMJDs, 
and may amplify the syndrome itself (82).
Finally, it has also been reported that 
TMJDs are associated with other condi-
tions such as FM, MPS, chronic fatigue 
syndrome, tension-type headache, and in-
terstitial cystitis (83). It has been demon-
strated that 75% of TMJDs patients could 
also be diagnosed as having FM and, con-
versely, that 18% of FM patients meet the 
diagnostic criteria for TMJDs (84). These 
chronic pain conditions probably share 
similar pathophysiological mechanisms. 
Although TMJDs are a localised disorder 
and FM is characterised by widespread 
pain, peripheral sensitisation and CS may 
be the link between them.
Benign joint hypermobility syndrome
JHS is the most frequent type of EDS 
(about 90%), a group of hereditary con-
nective tissue diseases characterised by 
joint hyperlaxity, mild skin hyperexten-
sibility, tissue fragility and extra-muscu-
loskeletal manifestations (85) (Tab. III). 
JHS and other types of EDS are genetical-
ly determined, and correspond to structur-
al damage typically localised in discrete 
anatomical sites; they therefore cannot be 
considered as belonging to the CSS fam-
ily. Nevertheless, some typical features 
and scientific reports of the frequent as-
sociation of JHS with some CSS (particu-
larly FM) suggests that there may be some 
pathophysiological correlations.
Pain is not one of the major diagnostic 
criteria of JHS; chronic joint, limb, and/
or back pain are only minor criteria that 
support but are not sufficient to establish a 
diagnosis (85). However, musculoskeletal 
pain is a frequent patient complaint and, 
although its relationship with hypermobil-
ity (HM) has not yet been defined, HM 
was the primary cause of musculoskeletal 
pain in most of the 6% of affected children 
at a pediatric clinic (86), and an associa-
tion between HM and soft tissue rheuma-
tism has been reported (87). The laxity 
of the joints could predispose some JHS 
patients to develop musculoskeletal pain, 
joint and muscle stiffness, and sometimes 
widespread pain (88).
Some authors have studied the possible 
relationship between JHS and FM but 
reached different conclusions (89-91). A 
historical editorial underlined the increas-
ing evidence that at least a sub-group of 
patients with soft tissue musculoskeletal 
pain, widespread pain, or FM were hyper-
mobile, and highlighted the fact that HM 
might be considered a contributing mech-
anism to the development of widespread 
pain or FM in some individuals (92). 
More recently, Turkish authors have dem-
onstrated that the frequency of joint HM 
was significantly higher in the FM groups 
than in the control groups of two different 
studies (respectively 64.2% vs 22%, and 
46.6 vs 28.8%) (93, 94).
HM is associated with specific and signif-
icant mechanical stresses at the joint and 
entheses. Migratory non-deforming mus-
culoskeletal pain is present in children 
and adults. As in the case of an overuse 
syndrome, some of these presentations 
may be due to repetitive or transient mi-
crotraumas (95).
Moreover, HM is also frequently associ-
ated with anxiety, panic attacks, and unex-
plained chest pain (96, 97), which are prob-
ably the expression of dysregulated auto-
nomic function. HM might be considered 
as a marker of the potential development 
of autonomic dysregulation, especially in 
the setting of intense or prolonged sympa-
thetic/fight-or-flight stimuli (95).
Impairment and the impact of pain have 
been recently studied in female patients 
Table III - Types of ehlers-Danlos syndrome.
Classic (Type i and ii)
Hypermobile type (Type iii)
vascular type (Type iv)
Kyphoscoliosis type (Type vi)
Arthrochalasia type (Types vii A and B)
Dermatosparaxis type (Type vii C) 
Other types
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with EDS HM type, the burden of which 
was compared with that of FM or rheu-
matoid arthritis. The EDS group reported 
similar physical and overall function, and 
better psychological function than the FM 
group, whereas their levels of pain sever-
ity, life interference, and affective distress 
were significantly lower (98).
In conclusion, JHS should be taken into 
account as a possible trigger of wide-
spread pain or FM in susceptible subjects. 
Excessive or inappropriate physical activ-
ity, with the consequent hyperextension of 
the joint capsule and repeated micro-trau-
mas of ligaments and muscles, could lead 
to the over-activation of pain receptors in 
the joints and, by causing hypersensitivity 
and amplifying pain signals, could gener-
ate more widespread pain or trigger the 
typical symptoms of FM.
n	 THERAPEUTIC APPROACHES
Treating the pain associated with FM and 
related conditions is a great challenge. Pain 
is the most frequent complaint of patients, 
especially those with the diseases described 
in this paper; clinicians are well aware of 
the fact that every treatment must take into 
account the associated symptoms, which 
need to be graded and prioritised. Various 
drug and non-drug therapies have proven 
positive effects on at least some CSS and, 
more generally, chronic pain.
Over the last few decades, substantial ad-
vances have been made in the treatment of 
these disorders, particularly for the phar-
macological options, on the basis of our 
greater understanding of the pathophysi-
ology of FM, our improved knowledge of 
CS mechanisms, and our ability to define 
symptom domains more precisely. Experts 
have pointed that a multidisciplinary ap-
proach is essential (99-103) as physicians 
need to bear in mind all of the potential co-
morbidities and overlapping conditions in 
order to avoid treatment failures and ensure 
that the most active problem is confronted 
in a timely and effective manner.
Well-designed and controlled clinical 
trials have shown that various classes of 
neuromodulatory agents can be helpful. 
Drugs that act on the noradrenergic and 
serotonergic pain pathways, or the as-
cending nociceptive pathways, and those 
that can improve other symptom domains 
such as fatigue, disturbed sleep and cogni-
tion, are available.
The treatment of FM is the most complete 
and extensively analysed, and the drugs 
that work well and have a high level of 
evidence in FM are also useful in some pa-
tients with other CSS. There is strong evi-
dence in favour of dual re-uptake inhibitors 
such as tricyclic compounds (amitriptyline, 
cyclobenzaprine) and serotonin-norepi-
nephrine reuptake inhibitors (milnacip-
ram, duloxetine, venlafaxine) and for an-
ticonvulsants (pregabalin and gabapentin); 
moderate evidence for tramadol, selective 
serotonin reuptake inhibitors, gamma hy-
droxybutyrate and dopamine agonists; 
and weak evidence for growth hormone, 
5-hydroxytriptamine, tropisetron, S-aden-
osyl-L-methionin. There is no evidence in 
favour of opioids, corticosteroids, non-ste-
roidal anti-inflammatory drugs (NSAIDs), 
or the benzodiazepines, and some data sug-
gest that giving opioids to patients with 
central pain states might even worsen the 
pain (1, 104, 105).
The European League Against Rheuma-
tism recommendations share this pharma-
cotherapeutic grading, but also strongly 
recommend tramadol and pramipexole 
and state the potential effectiveness of 
simple analgesics such as paracetamol 
and other weak opioids (99).
Ketamine, amitriptyline, and gabapentin 
are considered specifically effective in at-
tenuating CS (8).
No pharmacological options have ever 
been beneficial in treating MPS, for 
which the deactivation of TP is the gold 
standard; muscle stretching and TP injec-
tions are by far the most effective means 
of relieving symptoms (50, 52). Analge-
sics and non-steroidal anti-inflammatory 
drugs can modulate the pain, but have no 
definite action on TP. Muscle relaxants 
are not useful (106).
Medication is the main method of man-
aging the pain associated with TMJDs, 
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and the pharmacological options are not 
substantially different from those of other 
CSSs, particularly FM. Although many 
randomised and controlled clinical trials 
have been conducted to test these widely 
used drugs, a recent systematic review has 
shown that there is a lack of evidence in 
favour or against their use (75). 
The presence of a clearer peripheral origin 
of pain and consequent potential periph-
eral sensitisation probably supports the 
use of non-narcotic analgesics, NSAIDs, 
and weak and strong opioids in TMJD and 
JHS, reserving strong opioids to the sub-
set of patients who obtain no benefit from 
other therapies (107, 108).
Non-pharmacological therapies vary 
widely and it is often difficult to draw any 
conclusions concerning their value. How-
ever, physical therapy, the correction of 
abnormal postural or perpetuating factors, 
and different complementary and alterna-
tive medicines have often been suggested 
in order to improve the response to medi-
cation in a multidisciplinary manner and 
reduce the abnormal cycle of pain ampli-
fication and its related maladaptive and 
self-limiting behaviours (52, 85, 103, 109, 
110).
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